Skip to content

Early Intervention for High Risk Premyopic Children

Early Intervention for High Risk Premyopic Children: A Comparison Study of Defocus Integrated Multiple Segments Triple Enhanced Design Spectacle Lenses, 0.025% Atropine and Usual Care for Myopia Prevention

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07863713
Enrollment
240
Registered
2026-10-07
Start date
2026-10-24
Completion date
2033-10-24
Last updated
2026-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

myopia, DIMS TED, Atropine, Outdoor activities

Brief summary

The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.

Detailed description

With the increasing popularity of screen-based digital devices in the post-pandemic era, childhood myopia prevention and control has become a growing global challenge. Although the protective effect of increased outdoor time has been well established, the optimal strategy for preventing or delaying the onset of childhood myopia remains to be determined, particularly among pre-myopic children around the age of school entry. A substantial increase in myopia prevalence has been reported before and after entry into elementary school, and children with early-onset myopia are at increased risk of rapid progression and subsequent development of high myopia later in life. Recent evidence suggests that low-concentration atropine eye drops may reduce the incidence of childhood myopia. However, photophobia and other dose-related adverse effects associated with higher concentrations of atropine may interfere with daytime visual activities and potentially reduce children's willingness to engage in outdoor activities. In addition, evidence regarding optical interventions for the prevention of myopia onset remains limited. These unmet clinical needs motivate us to propose a randomized controlled trial evaluating optical and pharmacological approaches for myopia prevention using Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) spectacle lenses and 0.025% atropine eye drops, respectively, in pre-myopic preschool children aged 5-6 years. In this proposed study, we plan to recruit a total of 240 eligible participants identified as pre-myopic and asymptomatic through a population-based eye care program in Yilan County. Eligible participants will be randomly assigned to three groups: the DIMS TED spectacle lens group (n=80), the 0.025% atropine group (n=80), and the usual-care group (n=80). Because environmental and near-work demands are generally lower during preschool than after entry into elementary school, children assigned to the DIMS TED group will be instructed to wear the spectacles using a stepwise strategy: primarily at home and during near-work activities during the preschool stage, followed by full-time wear after entering elementary school. Cycloplegic spherical equivalent (SE) refraction and axial length will be measured every 6 months during the 7-year follow-up period. The primary outcome will be the change in mean cycloplegic SE over the study period among the three groups. Secondary outcomes will include the cumulative incidence of myopia, the cumulative proportion of participants exhibiting a fast myopic shift in SE, and changes in mean axial length over the study period. This proposed project may provide further evidence regarding early optical and pharmacological intervention strategies for myopia prevention and may support the development of an eye-care model emphasizing early identification and intervention for pre-myopic preschool children before or around the time of elementary school entry.

Interventions

Daily instillation of 0.025% atropine

DEVICEDIMS TED

Stepwise wearing of DIMS TED

Sponsors

National Yang Ming Chiao Tung University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 6 Years
Healthy volunteers
Yes

Inclusion criteria

* Age at enrollment: 5-6 years old (the senior grade of kindergarten) * Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): \< +1.00 D and \> -0.50 D * Astigmatism: 1.5 D or less in both eyes * Anisometropia: 1.50 D or less * Monocular uncorrected visual acuity: 6/7.5 or better in both eyes * Either of the parents with moderate myopia * Acceptance of random group allocation * Submission of complete informed consent.

Exclusion criteria

* Strabismus or any ocular motility disorder * Any ophthalmic and systemic disorders that might affect visual functions or refractive development * Previous treatment of atropine or other myopia control intervention

Design outcomes

Primary

MeasureTime frameDescription
Myopic shift of spherical equivalent refraction7 yearsThe change of mean cycloplegic spherical equivalent refraction over 7 years

Secondary

MeasureTime frameDescription
Axial length elongation7 yearsThe change of mean axial length over 7 years
Incidence of myopia7 yearsthe cumulative percentage of incident myopia
Fast myopic shift of spherical equivalent refraction7 yearsthe cumulative percentage of fast myopic shift of spherical equivalent refraction
Subfoveal choroidal thickness7 yearsthe vertical distance from the outer edge of the retinal pigment epithelium (or Bruch's membrane) to the inner surface of the sclera (the chorioscleral border) directly beneath the fovea

Contacts

CONTACTHsin-Yu Yang MD, MD
lisa771102@yahoo.com.tw+886 3 9325192
CONTACTDR.
lisa771102@yahoo.com.tw
PRINCIPAL_INVESTIGATORHsin-Yu Yang

National Yang Ming Chiao Tung University Hospital, Yilan, Taiw

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 8, 2026